product image
Regeneron’s cocktail antibody, REGN-COV2; J&J’s manufacturing-spree; ObsEva’s Yselty top-line studies

Jul 7, 2020

Regeneron Pharmaceuticals launches the Phase III trials of REGN-COV2 for treatment and prevention of COVID-19.   Regeneron is running two trials simultaneously, one for pr...

Read More
product image
FDA’s No to Intercept’s NASH Drug; Roche’s Phesgo gets approval; Gilead’s Remdesivir pricing

Jun 30, 2020

Intercept Pharmaceuticals receives a clear rejection from the FDA for its NASH drug, Obeticholic acid (OCA) Intercept Pharmaceuticals announced the issuance of a Complete R...

Read More
product image
Regeneron’s I-O Drug; Gene Therapy for Parkinson’s Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M

Jul 6, 2020

Regeneron recognizes new combos to boost I-O drug Libtayo’s cancer response PD-1/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patien...

Read More
product image
Sarepta & Codiak Inks $72.5M Deal; Invitae to Acquires ArcherDX; Merck announces V114’s Phase III result

Jul 6, 2020

Sarepta Therapeutics has announced a research and option alliance with Codiak BioSciences to design and develop engineered exosome therapeutics for neuromuscular diseases T...

Read More
product image
Lassen’s anti-IL-11 antibody; PTC’s COVID-19 trial; Lenzilumab’s result; Orca raises $192M

Jul 6, 2020

Lassen Therapeutics to create anti-IL-11 antibody for cancer and fibrosis Lassen Therapeutics is revealing USD 31 million from Frazier Healthcare Partners, Alta Venture and...

Read More
product image
Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ’s anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost

May 14, 2020

Merck supports Peloton Therapeutics with positive kidney cancer data Merck is revealing the data from a phase 2 study of a HIF-2α inhibitor after a year betting USD 1.05 b...

Read More
product image
In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit

Apr 14, 2020

Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients.  The company plans to explore the anti-inflammatory ...

Read More
product image
Ofev’s expanded use; Arkin Bio-Ventures II launch; USD 125 M for COVID-19 treatment

Mar 11, 2020

Boehringer Ingelheim’s Ofev (nintedanib) has received FDA recommendation for the treatment of chronic fibrosing interstitial lung diseases (ILD) with a progressive phenot...

Read More
product image
Gilead to buy Forty Seven; Akrevia Therapeutics unveils new identity; FDA approved pyrimethamine

Mar 3, 2020

Gilead Sciences has announced to purchase an Immuno-oncology company Forty Seven for USD 95.50 per share, totalling up to a deal value of USD 4.9 billion. By acquiring Fort...

Read More
product image
Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust

Feb 20, 2020

Incyte meets endpoint in the second pivotal atopic dermatitis clinical trial A second phase 3 trial of Incyte’s ruxolitinib cream in atopic dermatitis has hit its primary...

Read More
product image
Immune cells for age-related diseases; Regeneron’s antibody for 2019-nCoV; FDA nods for hydrogel injection

Feb 6, 2020

Activated immune cells responsible for improving age-related diseases  The main culprits of the inflammatory responses associated with asthma are Interleukins IL-33 and IL...

Read More
product image
First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed’s shares Soares

Feb 14, 2020

The US FDA has given its recommendation to the Aimmune Therapeutics’ drug, Palforzia, the first-ever treatment for Peanut Allergy. Palforzia is an oral immunotherapy, set...

Read More
product image
Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey

Feb 14, 2020

A Philadelphia-based pharmaceutical, Annovis Bio, has raised USD12 million by listing its 2 million shares at USD 6 each. The company has managed to net USD 2 million more ...

Read More
product image
Acceleron Pharma’s drug sotatercept touches the phase 2 mark; GT Medical receives nod for GammaTile; New treatment strategy for Parkinson’s disease

Feb 14, 2020

The drug, sotatercept of Acceleron Pharma, touches the phase 2 mark Acceleron Pharma, a clinical-stage biopharmaceutical company based in Boston, Massachusetts with a prima...

Read More
product image
Tepezza receives approval; a new way to treat Alzheimer’s

Jun 29, 2020

Horizon Therapeutics has become the first company to receive the regulatory approval of its drug Tepezza for the cure of Thyroid Eye Tepezza (teprotumumab-trbw) is the firs...

Read More